CN106243213A - A kind of tumor associated antigen XAGE 1b small peptide and application - Google Patents

A kind of tumor associated antigen XAGE 1b small peptide and application Download PDF

Info

Publication number
CN106243213A
CN106243213A CN201610669168.0A CN201610669168A CN106243213A CN 106243213 A CN106243213 A CN 106243213A CN 201610669168 A CN201610669168 A CN 201610669168A CN 106243213 A CN106243213 A CN 106243213A
Authority
CN
China
Prior art keywords
xage
cell
small peptide
tumor
ctl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201610669168.0A
Other languages
Chinese (zh)
Other versions
CN106243213B (en
Inventor
安军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhuhai Meiye Biotechnology Co ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201610669168.0A priority Critical patent/CN106243213B/en
Publication of CN106243213A publication Critical patent/CN106243213A/en
Application granted granted Critical
Publication of CN106243213B publication Critical patent/CN106243213B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention discloses a kind of tumor associated antigen XAGE 1b small peptide and application, the sequence of small peptide is SEQ ID NO:2～in SEQ ID NO:13 one.The CTL that the XAGE 1b antigenic peptides induction of the present invention is set up will not produce immunne response to testicular cell, a killing tumor cell.The ctl clone that induction obtains has good tumor cell specific lethal effect.Simultaneously during setting up CTL, inventor find the XAGE 1b antigenic peptides filtered out have the affinity suitable for HLA with on DC cell and can effectively stimulate, inducing producing specificity CTLs, illustrate that it possesses good polypeptide vaccine and the potentiality of DC vaccine.By clone's XAGE 1b antigenic peptides specificity TCR gene, build viral vector, transduction peripheral circulation CD8+T cell, obtain T cell (TCR T) clone that tcr gene is modified, there is the tumor cell specific lethal effect equally similar to parental generation CTL, point out it to have good clinical conversion and actual application prospect.

Description

A kind of tumor associated antigen XAGE-1b small peptide and application
Technical field
The present invention relates to tumor associated antigen peptide and application thereof, particularly to tumor associated antigen XAGE-1b small peptide and Application.
Background technology
It is known that T cell is adopted, treatment tumor is the technology attracted people's attention at present most, and especially receptor through engineering approaches T is thin The application of born of the same parents is just becoming soul-stirring cancer treatment method, infects virus equally and autoimmune disease has widely Application prospect.
Human immunity monitoring system important function in opposing Tumor Growth, immune surveillance system is each by coordinating Para-immunity cell is achieved the purpose of suppression tumor growth, wherein cytotoxic T cell (cytotoxic T Lymphocyte, CTLs) play the part of extremely important role, it is the lethal effect cell of most critical.Specific for tumour antigen CD8+T Cell can be with specific recognition direct killing tumor cell not to normal cell damage.Therefore T cell treatment becomes Optimal ideas of cancer therapy.America NI H was once foretold, cell therapy may become " can thoroughly cure the unique of tumor Means ".Therefore, it is thus achieved that can specific recognition, the CTL of killing tumor cell be the core for the treatment of tumor.Tumor is utilized to be correlated with Antigen (Tumor-associated antigen, TAA) polypeptid induction sets up tumor antigen peptide specific CTL, can obtain tool There is a ctl clone of specific killing tumor cell, and the T cell having clinical practice using value for next step exploitation is adopted and controlled Treating tumor and established important foundation, inventor can also obtain following achievement simultaneously:
1) these tumor associated antigen peptide amino acid sequence gone out through evaluation and screening, will can be used for building effective resisting Tumor peptide vaccine, DC vaccine；
2) inventor can be made to obtain the clear and definite TCR with specific recognition tumor antigen by molecule clone technology to compile Code gene, modifies the foundation of T cell for tcr gene.
3) by the fluorescent probe that synthesis is specific binding with small peptide, the molecular probe with independent intellectual property right can be developed Test kit, for early diagnosis and the treatment of nonsmall-cell lung cancer.
At present, φt cell receptor (T cell receptor, TCR) genetic modification T cell (TCR-T), such as chimeric antigen Receptor (chimeric antigen receptor, CAR) is modified T cell (CAR-T) technology and is equally received much attention.CAR-T applies Treat achieved with the curative effect attracted people's attention in neoplastic hematologic disorder.CAR is merged CD3 signal element by scFv, and its functional activity relies on In the sensitivity of signal element, signal element is made up of costimulatory molecules and (or) cytokine.But, there are research display, table The T cell reaching CAR is not so good as the T cell of express alpha β TCR heterodimer to the sensitivity of polypeptide.TCR-T is i.e. repaiied by tcr gene Decorations T cell technology, by the acquired TCR encoding gene transduction circulation CD8 with specific recognition tumor-antigen peptide+T is thin Born of the same parents, by this method can obtain within the extremely short time substantial amounts of stablize high expressed specificity TCR, have and parental generation CTL Same tumour-specific identification and the genetic modification T cell of lethal effect, thus needed for meeting practical clinical.
Inventor began to be engaged in the induction of tumor associated antigen peptide specific CTL and sets up from 2005, TCR correlational study (Int J Hematol.2011,93:176 185) and tcr gene modify the research of T cell, the most successfully by relevant for tumor anti- Former WT1 and Aurora kinase A specificity TCR transduction circulation CD8+T cell (Blood, 2011,118:1495-1503； Blood, 2012,119:368-376), it is thus achieved that TCR-T clones, through qualification external, internal it was confirmed its anti-lung cancer or leukemia The effectiveness of cell.
Tcr gene modify T cell technology increasingly show its important value in immunotherapy of tumors and fine before Scape, and the key precondition generating TCR-T is the TCR obtaining and having specific recognition tumor antigen, sets up tumor by external evoked Associated antigen polypeptide specific CTL is the important channel realizing this target.
XAGE-1 (X antigen family member 1) be Cancer-testis antigen (Cancer-Testis antigen, CTA) one of family member, CTA is also known as tumor-hair growth promoting system (Tumor-Germline, TG) antigen.Such antigen, is only expressed in Testicle spermatogonia, and it is not expressed in normal tissue cell, meanwhile, research finds that CTA is expressed in multiple histological types Tumor, thus be also called tomour specific and share antigen (tumor-specific shared antigens, TSSA).Due to testis Spermatogonium does not express major histocompatibility antigen complex (major histocompatibility complex, MHC) I Quasi-molecule, therefore the immunne response of the CTL of CTA induction is to testicular cell fanout free region, a killing tumor cell.Exactly because it is this Characteristic makes CTA become the preferable antigen of immunotherapy of tumors.Mankind XAGE-1 belongs to GAGE/PAGE family, XAGE-1 gene It is positioned Xp11.21-Xp11.22, including tetra-kinds of spliceosomes of XAGE-1a, XAGE-1b, XAGE-1c, XAGE-1d, XAGE-1b (X Antigen family, member 1b) full length gene 622bp, the amyloid protein precursor that coding is made up of 81 aminoacid.
XAGE-1b includes breast carcinoma, carcinoma of prostate, various types of pulmonary carcinoma (adenocarcinoma, scale cancer and minicell in kinds of tumors Pulmonary carcinoma etc.), ovarian cancer, melanoma, glioblastoma, lymphoma and leukemia etc. all have expression.This gene has XAGE- 1a, XAGE-1b, XAGE-1c and XAGE-1d4 kind transcribes isomer, and wherein XAGE-1b is can excellent by immunocyte identification Gesture antigen, immunogenicity is very strong, particularly high expressed in adenocarcinoma of lung in NSCLC, it has also become of pulmonary carcinoma immunization therapy is new Target spot.But, the most not yet there is the report of built vertical XAGE-1b antigenic peptides specific CTL.Although some CTA polypeptid specificities CTL has built up and passes through to identify, such as: NY-ESO-1 (New York esophageal squamous cell carcinoma 1) Peptide-specific CTL, MAGE antigen (melanoma-associated antigens), MAGE-1 specific CTL etc..But by Individual variation between the heterogeneity and tumor patient of tumor, it is thus achieved that abundant tumor antigen peptide specific CTL clone is The most necessary.
It is generally acknowledged that the length of polypeptide is the shortest, the specific immunity ability that it can be induced is the most weak, cannot induce the most completely Go out there is the ctl clone of therapeutic value；Otherwise, polypeptide length is the longest, more can induce specific CTL clone.But polypeptide Length is the longest, and synthesis difficulty is the biggest, is more difficult to obtain pure polypeptide, and the formation of clone is existed unpredictable by the existence of impurity peptide Impact, but and the high existence being still difficult to avoid that impurity peptide of the purification cost of polypeptide, the cost of this scheme is extremely large High.Accordingly it is desirable to shorten the length of polypeptide in the case of retaining polypeptide antigen as far as possible.CN102428102A is open Technical scheme in the part attempting intercepting in XAGE-1b antigen induce the humoral immunization to tumor or cellular immunization, but Being that its result is not satisfactory, the length of its polypeptide is not the most shorter than 16AA.
Small peptide there is likely to be the problem of poor specificity, how to obtain specificity good and have good immunogenic short Peptide is an extremely challenging job.
Summary of the invention
It is an object of the invention to provide tumor associated antigen XAGE-1b small peptide and application thereof.
The technical solution used in the present invention is:
XAGE-1b small peptide, its sequence is SEQ ID NO:2～in SEQ ID NO:13 one.
XAGE-1b small peptide as shown in SEQ ID NO:2～SEQ ID NO:13 can inducing tumor-specific cytotoxicity T The generation of cell.
The abductive approach of tumor-specific cytotoxicity T cell, uses SEQ ID NO:2's～SEQ ID NO:13 In XAGE-1b small peptide at least one is offered and CD8 through dendritic cell+T cell co-cultures, and induction screening obtains tomour specific Sexual cell cytotoxic T cell.
A kind of tumour polypeptide vaccine, is made up of active antigens composition and adjuvant, and active antigens composition is such as SEQ ID NO:2 ～at least one in SEQ ID NO:13XAGE-1b small peptide.
A kind of DC vaccine for oncotherapy, mainly by SEQ ID NO:2～the XAGE-1b small peptide of SEQ ID NO:13 In at least one and dendritic cell load obtain.
Selected by the present invention, small peptide high degree of specificity in nonsmall-cell lung cancer is expressed, by synthesis and SEQ ID The fluorescent probe that XAGE-1b small peptide shown in NO:2～SEQ ID NO:13 is specific binding, can develop and have independent intellectual property right The test kit of molecular probe, for early diagnosis and the treatment of nonsmall-cell lung cancer, and sets up relevant research platform.
The invention has the beneficial effects as follows:
The CTL that the XAGE-1b antigenic peptides induction of the present invention is set up will not produce immunne response to testicular cell, only kills swollen Oncocyte.The ctl clone that induction obtains has good tumor cell specific lethal effect.Simultaneously during setting up CTL, Inventor finds that the XAGE-1b antigenic peptides filtered out has the affinity suitable for HLA with on DC cell and can effectively stimulate, lure The raw specific CTL s of artificial deliviery, illustrates that it possesses good polypeptide vaccine and the potentiality of DC vaccine.By clone's XAGE-1b antigenic peptides Specificity TCR gene, builds viral vector, peripheral circulation CD8+T cell of transduceing, it is thus achieved that the T cell (TCR-that tcr gene is modified T) clone, has the tumor cell specific lethal effect similar to parental generation CTL equally, points out it to have good clinical conversion And actual application prospect.
Accompanying drawing explanation
Fig. 1 is XAGE-1b expression in lung adenocarcinoma cell；
Fig. 2 is XAGE-1b (51-59) specific CTL IFN-γ release test；
Fig. 3 is XAGE-1b (62-70) specific CTL IFN-γ release test.
Detailed description of the invention
Tumor antigen selects XAGE-1b antigen, and XAGE-1b gene is positioned at X chromosome (Xp11.21-Xp11.22), total length 622bp, the amyloid protein precursor that coding is made up of 81 aminoacid.Aminoacid sequence (is derived from GenBank:NM_ as follows 001097594.2):
MESPKKKNQQLKVGILHLGSRQKKIRIQLRSQCATWKVICKSCISQTPGINLDLGSGVKVKIIPKEEHCKMPEAGEE QPQV (SEQ ID NO:1)
Below in conjunction with experiment, further illustrate technical scheme.
XAGE-1b expression in nonsmall-cell lung cancer
XAGE-1 is important member in CTA family, in addition to having wide expression in nonsmall-cell lung cancer, in multiple evil Property tumor there is expression, sets up XAGE-1b antigenic peptides specific CTL clone and be extremely important.Early-stage Study is sent out A person of good sense randomly selects surgical resection lung cancer specimen (all making a definite diagnosis and obtain patient through pathologic finding to agree to), conventional line RT-PCR Detection XAGE-1b mRNA expression (PCR primer: F:5'-TTTCTCCGCTACTGAGACAC-3'(SEQ in NSCLC ID NO:14), R:5'-CAGGTGCTGGGAAGGGAAAT-3'(SEQ ID NO:15)).Result such as Fig. 1, display XAGE-1b exist Lung adenocarcinoma cell has wide expression.
Inventor, by own method, carries out comprehensive grading to the CTL epi-position of XAGE-1b antigen, with two different numbers According to storehouse (US National Institutes of Health Research Institute BIMAS, http://www-bimas.cit.nih.gov/molbio/hla_bind/ and Heidelberg, Germany biomedical information center SYFPEITHI, http://www.syfpeithi.de/) product of scoring is that this is pre- Survey the overall score of epi-position, predict the epi-position of its CTL according to overall score.Gained candidate peptide is synthesized by specialized company.Concrete polypeptide sequence Row basis and different HLA hypotype combining classifications, specific as follows:
HLA-A*1101 group:
Based on predicting the outcome, inventor randomly chooses 2 therein and carries out result verification, and specific experiment is as follows.
The operation that XAGE-1b small peptide specific CTL clone is set up is as follows:
The 10 of same healthy donor5Individual CD8+T cell is by loading the 10 of XAGE-1b (57-65) peptide4Between individual Mo-DCs After stimulating 2 times every 1 week, then by autologous 105The PBMC of the load XAGE-1b small peptide that individual ametycin processed stimulates 1 time After, obtain through standard cell lines poison experiment sieving.
T2 cell loads 5uM XAGE-1b small peptide and leads to as target cell, the XAGE-1b small peptide specific cytotoxicity of CTL Cross LDH release test to be confirmed.
Using the above external evoked method setting up XAGE-1b small peptide specific CTL clone, inventor has also set up HLA- The restricted XAGE-1b of A*1101 (51-59) (SEQ ID NO:5) and XAGE-1b (62-70) (SEQ ID NO:7) specific CTL Clone, confirms its polypeptid specificity effect of immune response (such as Fig. 2,3) by IFN-γ release test.
Above-mentioned experimental data shows, the CTL epi-position that inventor sets up is extremely effective, it was predicted that result accords with experimental result Conjunction property is the best.
It is visible, by least one (SEQ ID NO:2～13) in above-mentioned XAGE-1b small peptide is carried through dendritic cell Co-culture in cytotoxicity T lymphocytes, screening can be induced to obtain specific for tumour antigen cytotoxic T lymphocyte.This Plant specific for tumour antigen cytotoxic T lymphocyte and can be used for the treatment of tumor.
By at least one (SEQ ID NO:2～13) in above-mentioned XAGE-1b small peptide and dendritic cell (dendritic Cell, DC) load feedback, body can be stimulated to produce polypeptid specificity antitumor T thin as DC vaccine for tumour immunity Born of the same parents, and then realize the treatment of tumor.
At least one (SEQ ID NO:2～13) in above-mentioned XAGE-1b small peptide may be used for measuring in subject sample For the antibody horizontal of polypeptide, and then for the diagnosis of nonsmall-cell lung cancer.
The XAGE-1b small peptide length of the present invention is only 9 aminoacid, and chemosynthesis difficulty is little, can be directly synthesized and obtain High-purity product, application cost is substantially reduced, simultaneously definite effect, has good application potential.
<110>peace, army
, bud
<120>a kind of tumor associated antigen XAGE-1b small peptide and application
<130> XAGE-1b*1101
<160> 15
<170> PatentIn version 3.5
<210> 1
<211> 81
<212> PRT
<213>mankind
<400> 1
Met Glu Ser Pro Lys Lys Lys Asn Gln Gln Leu Lys Val Gly Ile Leu
1 5 10 15
His Leu Gly Ser Arg Gln Lys Lys Ile Arg Ile Gln Leu Arg Ser Gln
20 25 30
Cys Ala Thr Trp Lys Val Ile Cys Lys Ser Cys Ile Ser Gln Thr Pro
35 40 45
Gly Ile Asn Leu Asp Leu Gly Ser Gly Val Lys Val Lys Ile Ile Pro
50 55 60
Lys Glu Glu His Cys Lys Met Pro Glu Ala Gly Glu Glu Gln Pro Gln
65 70 75 80
Val
<210> 2
<211> 9
<212> PRT
<213>mankind
<400> 2
Gly Val Lys Val Lys Ile Ile Pro Lys
1 5
<210> 3
<211> 9
<212> PRT
<213>mankind
<400> 3
Asp Leu Gly Ser Gly Val Lys Val Lys
1 5
<210> 4
<211> 9
<212> PRT
<213>mankind
<400> 4
Gly Ser Arg Gln Lys Lys Ile Arg Ile
1 5
<210> 5
<211> 9
<212> PRT
<213>mankind
<400> 5
Asn Leu Asp Leu Gly Ser Gly Val Lys
1 5
<210> 6
<211> 9
<212> PRT
<213>mankind
<400> 6
Ile Leu His Leu Gly Ser Arg Gln Lys
1 5
<210> 7
<211> 9
<212> PRT
<213>mankind
<400> 7
Ile Ile Pro Lys Glu Glu His Cys Lys
1 5
<210> 8
<211> 9
<212> PRT
<213>mankind
<400> 8
Cys Ala Thr Trp Lys Val Ile Cys Lys
1 5
<210> 9
<211> 9
<212> PRT
<213>mankind
<400> 9
Ile Ser Gln Thr Pro Gly Ile Asn Leu
1 5
<210> 10
<211> 9
<212> PRT
<213>mankind
<400> 10
Gln Thr Pro Gly Ile Asn Leu Asp Leu
1 5
<210> 11
<211> 9
<212> PRT
<213>mankind
<400> 11
Gly Ser Gly Val Lys Val Lys Ile Ile
1 5
<210> 12
<211> 9
<212> PRT
<213>mankind
<400> 12
Lys Val Gly Ile Leu His Leu Gly Ser
1 5
<210> 13
<211> 9
<212> PRT
<213>mankind
<400> 13
Ala Thr Trp Lys Val Ile Cys Lys Ser
1 5
<210> 14
<211> 20
<212> DNA
<213>artificial primer
<400> 14
tttctccgct actgagacac 20
<210> 15
<211> 20
<212> DNA
<213>artificial primer
<400> 15
caggtgctgg gaagggaaat 20

Claims (6)

1.XAGE-1b small peptide, its sequence is SEQ ID NO:2～in SEQ ID NO:13 one.
The application in tumor-specific cytotoxicity T cell clone is prepared in induction of the 2.XAGE-1b small peptide, wherein, XAGE-1b is short Peptide is as claimed in claim 1.
3. the abductive approach of tumor-specific cytotoxicity T cell, it is characterised in that: use the XAGE-1b described in claim 1 In small peptide at least one is offered and CD8 through dendritic cell+T cell co-cultures, and induction screening obtains tumor specific cell Cytotoxic T cell.
4. a tumour polypeptide vaccine, is made up of active antigens composition and adjuvant, it is characterised in that: active antigens composition is such as power Profit requires at least one in XAGE-1b small peptide described in 1.
5. for a DC vaccine for oncotherapy, mainly by least one He in the XAGE-1b small peptide described in claim 1 Dendritic cell loads and obtains.
The application in preparing Diagnosis of Non-Small Cell Lung test kit of the 6.XAGE-1b small peptide, wherein, XAGE-1b small peptide such as right Require described in 1.
CN201610669168.0A 2016-08-15 2016-08-15 A kind of tumor associated antigen XAGE-1b small peptides and application Active CN106243213B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610669168.0A CN106243213B (en) 2016-08-15 2016-08-15 A kind of tumor associated antigen XAGE-1b small peptides and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610669168.0A CN106243213B (en) 2016-08-15 2016-08-15 A kind of tumor associated antigen XAGE-1b small peptides and application

Publications (2)

Publication Number Publication Date
CN106243213A true CN106243213A (en) 2016-12-21
CN106243213B CN106243213B (en) 2018-11-09

Family

ID=57592686

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610669168.0A Active CN106243213B (en) 2016-08-15 2016-08-15 A kind of tumor associated antigen XAGE-1b small peptides and application

Country Status (1)

Country Link
CN (1) CN106243213B (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109988748A (en) * 2017-12-29 2019-07-09 深圳华大生命科学研究院 A method of tumor specific T cells are screened from TIL
CN111057135A (en) * 2019-12-23 2020-04-24 维塔恩(广州)医药有限公司 Tumor-associated gene FBXW7 mutation-associated antigen short peptide and application thereof
CN111072763A (en) * 2019-12-23 2020-04-28 维塔恩(广州)医药有限公司 Tumor-associated gene GNAS mutation-associated antigen short peptide and application thereof
CN111087448A (en) * 2019-12-23 2020-05-01 维塔恩(广州)医药有限公司 Tumor-associated gene JAK2 mutation-associated antigen short peptide and application thereof
CN111116734A (en) * 2019-12-23 2020-05-08 维塔恩(广州)医药有限公司 Tumor-associated gene c-kit mutation-associated antigen short peptide and application thereof
CN111171136A (en) * 2019-12-23 2020-05-19 维塔恩(广州)医药有限公司 tumor-associated gene PDGFR α mutation-associated antigen short peptide and application thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211510A1 (en) * 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2005058944A2 (en) * 2003-12-12 2005-06-30 The Government Of The United States, As Represented By The Secretary Of The Department Of Health & Human Services Immunogenic peptides fragments of xage-1
WO2005114203A2 (en) * 2004-05-20 2005-12-01 The Regents Of The University Of California Dominant b cell epitopes and methods of making and using thereof
CN1872877A (en) * 2005-06-03 2006-12-06 北京大学 Idiosyncratic antigen protein, and antigen peptide of liver cancer orchis pellet
CN101501069A (en) * 2006-04-11 2009-08-05 株式会社免疫新领域 Protein complex and process for production thereof
CN102428102A (en) * 2009-05-22 2012-04-25 国立大学法人冈山大学 Peptide inducing xage-1b-specific immune reaction and utilization of same
CN105101998A (en) * 2013-02-12 2015-11-25 得克萨斯技术大学联合体 Composition and method for diagnosis and immunotherapy of lung cancer

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211510A1 (en) * 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2005058944A2 (en) * 2003-12-12 2005-06-30 The Government Of The United States, As Represented By The Secretary Of The Department Of Health & Human Services Immunogenic peptides fragments of xage-1
WO2005114203A2 (en) * 2004-05-20 2005-12-01 The Regents Of The University Of California Dominant b cell epitopes and methods of making and using thereof
CN1872877A (en) * 2005-06-03 2006-12-06 北京大学 Idiosyncratic antigen protein, and antigen peptide of liver cancer orchis pellet
CN101501069A (en) * 2006-04-11 2009-08-05 株式会社免疫新领域 Protein complex and process for production thereof
CN102428102A (en) * 2009-05-22 2012-04-25 国立大学法人冈山大学 Peptide inducing xage-1b-specific immune reaction and utilization of same
CN105101998A (en) * 2013-02-12 2015-11-25 得克萨斯技术大学联合体 Composition and method for diagnosis and immunotherapy of lung cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JUNJI KAWADA, ET.,AL.: "Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination", 《INTERNATIONAL JOURNAL OF CANCER》 *
MICHIHIDE SHIMONO, ET AL.: "Identification of DR9-restricted XAGE antigen on lung adenocarcinoma recognized by autologous CD4 T-cells", 《INTERNATIONAL JOURNAL OF ONCOLOGY》 *
YOSHIYUKI MORISHITA , ET AL.: "HLA-DRB1*0410-Restricted Recognition of XAGE-1b37-48 Peptide by CD4 T Cells", 《MICROBIOL. IMMUNOL》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109988748A (en) * 2017-12-29 2019-07-09 深圳华大生命科学研究院 A method of tumor specific T cells are screened from TIL
CN111057135A (en) * 2019-12-23 2020-04-24 维塔恩(广州)医药有限公司 Tumor-associated gene FBXW7 mutation-associated antigen short peptide and application thereof
CN111072763A (en) * 2019-12-23 2020-04-28 维塔恩(广州)医药有限公司 Tumor-associated gene GNAS mutation-associated antigen short peptide and application thereof
CN111087448A (en) * 2019-12-23 2020-05-01 维塔恩(广州)医药有限公司 Tumor-associated gene JAK2 mutation-associated antigen short peptide and application thereof
CN111116734A (en) * 2019-12-23 2020-05-08 维塔恩(广州)医药有限公司 Tumor-associated gene c-kit mutation-associated antigen short peptide and application thereof
CN111171136A (en) * 2019-12-23 2020-05-19 维塔恩(广州)医药有限公司 tumor-associated gene PDGFR α mutation-associated antigen short peptide and application thereof

Also Published As

Publication number Publication date
CN106243213B (en) 2018-11-09

Similar Documents

Publication Publication Date Title
CN106243213B (en) A kind of tumor associated antigen XAGE-1b small peptides and application
JP6435286B2 (en) Cancer vaccine composition
KR101391561B1 (en) -*3303 1 hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same
JP6145475B2 (en) Cancer antigen helper peptide
CN106279392B (en) Tumor associated antigen XAGE-1b small peptides and its application
CN109970846A (en) A kind of tumor associated antigen XAGE-1b nonapeptide and its application
JP5934897B2 (en) T cell receptor β chain gene and α chain gene
CN103570818B (en) Tumor antigenic polypeptide and the purposes as tumor vaccine thereof
TW202015720A (en) Neoantigens and uses thereof
WO2016093243A1 (en) Tumor antigen peptide
CN105753978A (en) HLA-A11 restricted and carcino-embryonic antigen originated epitope peptide and application thereof
CN106279391B (en) Tumor associated antigen XAGE-1b small peptide and application
WO2017115798A1 (en) Tumor antigen peptide
EP2363468B1 (en) Tumor antigen peptide and use thereof
CN109790224A (en) Tumor-antigen peptide and its application derived from CACNA1H
CN110016073A (en) A kind of XAGE-1b nonapeptide and its application
WO2018058490A1 (en) Col14a1-derived tumour antigen polypeptide and use thereof
Kaplan et al. Interferon-γ renders tumors that express low levels of Her-2/neu sensitive to cytotoxic T cells
Yang et al. Identification of new HLA-A* 0201-restricted cytotoxic T lymphocyte epitopes from neuritin
KR101203979B1 (en) Method for identifying novel tumor antigen by using RNA-transduced antigen presenting cells
JP2002360251A (en) Hla-a24-restricted tumor antigen peptide derived from mn/ca9
JP2009035534A (en) Hla-a24-binding antigen peptide and use thereof
Baxevanis et al. HER2/neu as a target for vaccine and antibody-directed therapies
JP2004121051A (en) Human cancer spermary antigen

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
CB03 Change of inventor or designer information

Inventor after: Zhang Bei

Inventor before: An Jun

COR Change of bibliographic data
TA01 Transfer of patent application right

Effective date of registration: 20170104

Address after: 510630 Tianhe Road, Guangzhou, Guangdong, No. 600, No.

Applicant after: Zhang Bei

Address before: 510630 Tianhe Road, Guangzhou, Guangdong, No. 600, No.

Applicant before: An Jun

Applicant before: Zhang Bei

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20180928

Address after: 510660 201 building, two building, 5 11 Nanxiang three road, Whampoa District, Guangzhou, Guangdong.

Applicant after: Guangzhou an Botai Medical Biotechnology Co.,Ltd.

Address before: 510630 600 Tianhe Road, Tianhe District, Guangzhou, Guangdong

Applicant before: Zhang Bei

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20210120

Address after: Unit 16 and 17, 25th floor, building a, Guanzhou life science innovation center, No. 51, helix Avenue, International Biological Island, Huangpu District, Guangzhou City, Guangdong Province, 510555

Patentee after: Yinmei Biotechnology (Guangzhou) Co.,Ltd.

Address before: 510660 201 building, two building, 5 11 Nanxiang three road, Whampoa District, Guangzhou, Guangdong.

Patentee before: Guangzhou an Botai Medical Biotechnology Co.,Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20220718

Address after: 510665 room 213, Xiangshan Road, high tech Industrial Development Zone, Guangzhou, Guangdong, China, 19

Patentee after: GUANGZHOU MEISA BIOTECHNOLOGY CO.,LTD.

Address before: Unit 16 and 17, 25th floor, building a, Guanzhou life science innovation center, No. 51, helix Avenue, International Biological Island, Huangpu District, Guangzhou City, Guangdong Province, 510555

Patentee before: Yinmei Biotechnology (Guangzhou) Co.,Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20230612

Address after: 519075, 5-139, 5th Floor, Yunxi Valley Digital Industrial Park, No. 168 Youyou Road, Xiangzhou District, Zhuhai City, Guangdong Province (Block B, Meixi Commercial Plaza)

Patentee after: Zhuhai Meiye Biotechnology Co.,Ltd.

Address before: 510665 room 213, Xiangshan Road, high tech Industrial Development Zone, Guangzhou, Guangdong, China, 19

Patentee before: GUANGZHOU MEISA BIOTECHNOLOGY CO.,LTD.

TR01 Transfer of patent right